What’s the current market cap for Candel Therapeutics stock?

Candel Therapeutics (CADL) has a market cap of $627m as of June 16, 2026.

What is the P/E ratio for Candel Therapeutics stock?

The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of June 16, 2026.

Does Candel Therapeutics stock pay dividends?

No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Candel Therapeutics dividend payment date?

Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.

What is the beta indicator for Candel Therapeutics?

Candel Therapeutics (CADL) has a beta rating of -0.59. This means that it has an inverse relation to market volatility.

Buy Candel Therapeutics stock | $CADL Share Price

13:30

15:10

16:45

18:25

20:00

About Candel Therapeutics

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Ticker

$CADL

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Needham, United States

Website

www.candeltx.com

CADL Metrics

BasicAdvanced

$627m

-$0.97

-0.59

Bulls say / Bears say

Extended phase 3 follow-up data showed CAN-2409 reduced prostate-cancer recurrence risk by 39% at a median 58-month follow-up, bolstering the case for regulatory approval and market adoption (Reuters)

The April 2026 commercialization agreement with EVERSANA provides a turnkey U.S. launch infrastructure—covering data analytics, medical affairs, market access and field operations—accelerating potential market entry without building an internal sales force (EVERSANA)

A $100 million royalty funding deal with RTW Investments secures non-dilutive capital contingent on FDA approval, extending runway and reducing near-term equity-raising needs (GlobeNewswire)

Candel reported a Q1 2026 net loss of $8.86 million, driven by higher R&D and commercial-readiness expenses, highlighting ongoing cash-burn risks despite a stated runway into Q1 2028 (Reuters)

The company priced a public offering of 18,348,624 shares at $5.45 each—raising gross proceeds of $100 million—which increases share count by over 33% and may pressure existing shareholders (Reuters)

Candel plans to submit its BLA for CAN-2409 in Q4 2026, and any regulatory delays or FDA requirements not being met could postpone commercialization and strain finances further (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CADL

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

A $100 million royalty funding deal with RTW Investments secures non-dilutive capital contingent on FDA approval, extending runway and reducing near-term equity-raising needs (GlobeNewswire)

Candel reported a Q1 2026 net loss of $8.86 million, driven by higher R&D and commercial-readiness expenses, highlighting ongoing cash-burn risks despite a stated runway into Q1 2028 (Reuters)

Candel plans to submit its BLA for CAN-2409 in Q4 2026, and any regulatory delays or FDA requirements not being met could postpone commercialization and strain finances further (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.